Published in N Engl J Med on March 31, 2009
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ (2010) 28.70
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med (2012) 5.69
Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet (2014) 3.73
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 3.48
Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology (2014) 3.36
The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke (2011) 2.35
Moving the tipping point: the decision to anticoagulate patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes (2010) 2.17
ASA failure: does the combination ASA/clopidogrel confer better long-term vascular protection? Neurology (2014) 2.08
Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. Europace (2015) 1.98
Clinical features and racial/ethnic differences among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. J Stroke Cerebrovasc Dis (2012) 1.47
A randomized, double-blind, placebo-controlled study of rebamipide for gastric mucosal injury taking aspirin with or without clopidogrel. Dig Dis Sci (2014) 1.44
Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. Europace (2013) 1.40
Association of cyclooxygenase-2 genetic variant with cardiovascular disease. Eur Heart J (2014) 1.39
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design. Int J Stroke (2013) 1.29
Effect of addition of clopidogrel to aspirin on mortality: systematic review of randomized trials. Stroke (2012) 1.23
Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol (2012) 1.23
The role of aspirin for stroke prevention in atrial fibrillation. Nat Rev Cardiol (2011) 1.14
Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol (2010) 1.13
Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier. Proc Natl Acad Sci U S A (2016) 1.12
Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. Neurology (2012) 1.05
Pharmacogenetics and cardiovascular disease--implications for personalized medicine. Pharmacol Rev (2013) 1.04
European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. Eur J Prev Cardiol (2015) 0.99
Significant increase in clopidogrel use across U.S. children's hospitals. Pediatr Cardiol (2010) 0.97
Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo) (2011) 0.97
Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis (2012) 0.93
Atrial fibrillation in the elderly. J Geriatr Cardiol (2012) 0.90
Effect of addition of clopidogrel to aspirin on stroke incidence: Meta-analysis of randomized trials. Int J Stroke (2013) 0.90
Feasibility of TEE-guided stroke risk assessment in atrial fibrillation-background, aims, design and baseline data of the TIARA pilot study. Neth Heart J (2011) 0.88
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol (2009) 0.88
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open (2014) 0.87
Antithrombotic medication for cardioembolic stroke prevention. Stroke Res Treat (2011) 0.87
Treatment of risk factors to prevent stroke. Neurotherapeutics (2011) 0.86
Prevention of cardioembolic stroke. Neurotherapeutics (2011) 0.85
Antiplatelet agents for stroke prevention. Neurotherapeutics (2011) 0.85
Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease. Clin Med Insights Cardiol (2010) 0.85
Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proc Intensive Care Cardiovasc Anesth (2013) 0.84
Review of atrial fibrillation outcome trials of oral anticoagulant and antiplatelet agents. Europace (2012) 0.84
Present concepts in management of atrial fibrillation: From drug therapy to ablation. World J Cardiol (2009) 0.84
The pharmacogenetics of antiplatelet agents: towards personalized therapy? Nat Rev Cardiol (2011) 0.84
Stroke prevention: managing modifiable risk factors. Stroke Res Treat (2012) 0.83
Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group. Circulation (2012) 0.83
Recent advances in the pharmacogenetics of clopidogrel. Hum Genet (2011) 0.83
Study protocol: the DESPATCH study: delivering stroke prevention for patients with atrial fibrillation - a cluster randomised controlled trial in primary healthcare. Implement Sci (2011) 0.83
Role of cytochrome P450 genotype in the steps toward personalized drug therapy. Pharmgenomics Pers Med (2011) 0.83
Efficacy and safety of adding clopidogrel to aspirin on stroke prevention among high vascular risk patients: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.82
Stroke Prevention in Atrial Fibrillation: Where are We Now? Clin Med Insights Cardiol (2012) 0.82
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
Cost of atrial fibrillation: invasive vs non-invasive management in 2012. Curr Cardiol Rev (2012) 0.82
The Korean Heart Rhythm Society's 2014 Statement on Antithrombotic Therapy for Patients with Nonvalvular Atrial Fibrillation: Korean Heart Rhythm Society. Korean Circ J (2015) 0.82
Antiplatelets in secondary stroke prevention. Front Neurol (2011) 0.82
Evidence-based percutaneous closure of the left atrial appendage in patients with atrial fibrillation. Curr Cardiol Rev (2012) 0.81
A meta-analysis of left atrial appendage closure for stroke prevention in atrial fibrillation-adding to the debate but elements remain unresolved. J Thorac Dis (2015) 0.81
Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly. Circulation (2015) 0.81
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke (2015) 0.80
Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clin Pharmacol (2016) 0.80
Effects of combined aspirin and clopidogrel therapy on cardiovascular outcomes: a systematic review and meta-analysis. PLoS One (2012) 0.79
Anticoagulation in Patients Aged ≥75 years with Atrial Fibrillation: Role of Novel Oral Anticoagulants. Cardiol Ther (2013) 0.79
Current status of antiplatelet agents to prevent stroke. Curr Neurol Neurosci Rep (2011) 0.79
Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy. Sci Rep (2015) 0.79
Effects of low-dose aspirin and fish oil on platelet function and NF-kappaB in adults with diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids (2013) 0.79
Management of stroke prevention in canadian patients with atrial fibrillation at moderate to high risk of stroke. Can J Hosp Pharm (2013) 0.78
Comparative effect of clopidogrel and aspirin versus aspirin alone on laboratory parameters: a retrospective, observational, cohort study. Cardiovasc Diabetol (2013) 0.78
Anticoagulant and antiplatelet therapy in patients with atrial fibrillation and coronary artery disease. Thrombosis (2012) 0.78
Combination aspirin and clopidogrel for secondary prevention of ischemic stroke. Curr Treat Options Cardiovasc Med (2013) 0.78
Epidemiology, Risk Factors, and Clinical Features of Intracerebral Hemorrhage: An Update. J Stroke (2017) 0.78
Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. Can J Hosp Pharm (2016) 0.77
New oral anticoagulants: are coagulation units still required? Thromb J (2014) 0.77
Newer anticoagulants for non-valvular atrial fibrillation. Pharmaceuticals (Basel) (2012) 0.77
Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clin Interv Aging (2013) 0.77
The ACTIVE pursuit of stroke prevention in patients with atrial fibrillation. N Engl J Med (2009) 0.77
Cost considerations in the management of atrial fibrillation - impact of dronedarone. Clinicoecon Outcomes Res (2012) 0.77
Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev (2013) 0.77
Update on antithrombotic therapy for stroke prevention in atrial fibrillation. Curr Treat Options Cardiovasc Med (2010) 0.77
Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. Europace (2016) 0.77
Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options. J Interv Card Electrophysiol (2012) 0.77
Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. Med Devices (Auckl) (2015) 0.76
How to walk the tightrope between harm and protection in selecting the optimal antiplatelet treatment strategy after transcatheter left atrial appendage occlusion. Postepy Kardiol Interwencyjnej (2015) 0.76
Managing peptic ulcer and gastroesophageal reflux disease in elderly Chinese patients--focus on esomeprazole. Clin Interv Aging (2013) 0.76
Surgical ablation for atrial fibrillation: an editorial. J Thorac Dis (2015) 0.76
Antiplatelet therapy in secondary stroke prevention--state of the art. J Cell Mol Med (2010) 0.76
Current issues in antiplatelet therapy for stroke prevention: the importance of stroke subtypes and differences between stroke and MI patients. J Neurol (2010) 0.76
Supporting Treatment decision making to Optimise the Prevention of STROKE in Atrial Fibrillation: the STOP STROKE in AF study. Protocol for a cluster randomised controlled trial. Implement Sci (2012) 0.76
Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J Am Heart Assoc (2016) 0.75
The combination of clopidogrel plus aspirin to treat atrial fibrillation. Curr Cardiol Rep (2010) 0.75
Combination of clopidogrel and aspirin for reduction of vascular events in patients with atrial fibrillation. Expert Rev Cardiovasc Ther (2009) 0.75
ACTIVE A: balancing the benefits and risks of clopidogrel and aspirin. Lancet Neurol (2009) 0.75
Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med (2009) 0.75
Refining the role of antiplatelet therapy for atrial fibrillation. Curr Cardiol Rep (2009) 0.75
ACP Journal Club. In patients with atrial fibrillation, adding clopidogrel to aspirin reduced major vascular events but increased bleeding. Ann Intern Med (2009) 0.75
Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med (2009) 0.75
Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med (2009) 0.75
Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med (2009) 0.75
Clopidogrel plus aspirin in atrial fibrillation. N Engl J Med (2009) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med (2008) 19.76
Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med (1991) 16.19
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet (2008) 13.15
Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med (2006) 11.72
Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet (2010) 11.25
Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med (2013) 11.14
Subclinical atrial fibrillation and the risk of stroke. N Engl J Med (2012) 11.11
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med (2004) 10.02
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Apixaban in patients with atrial fibrillation. N Engl J Med (2011) 9.97
Effect of ramipril on the incidence of diabetes. N Engl J Med (2006) 9.69
Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med (2011) 8.93
Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med (2009) 8.51
Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. Lancet (2011) 8.49
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Randomized trial of primary PCI with or without routine manual thrombectomy. N Engl J Med (2015) 7.83
Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med (2014) 7.54
Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA (2005) 7.35
Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet (2010) 7.08
Guidelines for the primary prevention of stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2010) 6.93
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA (2005) 6.81
Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med (2014) 6.65
Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation (2011) 6.48
Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. JAMA (2007) 6.38
Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med (2008) 6.17
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med (2012) 6.16
Aspirin in patients undergoing noncardiac surgery. N Engl J Med (2014) 6.10
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med (2008) 6.08
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med (2010) 6.05
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. Lancet (2006) 5.85
Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation (2002) 5.79
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med (2007) 5.78
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA (2006) 5.74
Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med (2012) 5.69
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int (2011) 5.47
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med (2015) 5.31
Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation (2005) 5.29
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet (2008) 5.27
Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med (2006) 5.24
Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA (2013) 5.19
Use of ramipril in preventing stroke: double blind randomised trial. BMJ (2002) 4.91
Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J (2007) 4.88
Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med (2014) 4.86
Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med (2009) 4.83
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA (2011) 4.68
Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA (2012) 4.58
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med (2015) 4.50